-
Je něco špatně v tomto záznamu ?
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk
PC. Smits, E. Frigoli, P. Vranckx, Y. Ozaki, MC. Morice, B. Chevalier, Y. Onuma, S. Windecker, PAL. Tonino, M. Roffi, M. Lesiak, F. Mahfoud, J. Bartunek, D. Hildick-Smith, A. Colombo, G. Stankovic, A. Iñiguez, C. Schultz, R. Kornowski, PJL. Ong,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 1983 do Před 1 rokem
Open Access Digital Library
od 1998-01-01
- MeSH
- antikoagulancia terapeutické užití MeSH
- dimaprit analogy a deriváty MeSH
- infarkt myokardu * farmakoterapie MeSH
- inhibitory agregace trombocytů škodlivé účinky MeSH
- kombinovaná farmakoterapie MeSH
- koronární angioplastika * metody MeSH
- krvácení chemicky indukované epidemiologie MeSH
- lidé MeSH
- polymery MeSH
- stenty MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. OBJECTIVES: The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction. METHODS: In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. RESULTS: NACE and MACCE did not differ with abbreviated vs nonabbreviated APT regimens in patients with an acute or recent myocardial infarction (n = 1,780; HR: 0.83; 95% CI: 0.61-1.12 and HR: 0.86; 95% CI: 0.62-1.19, respectively) or without an acute or recent myocardial infarction (n = 2,799; HR: 1.03; 95% CI: 0.77-1.38 and HR: 1.13; 95% CI: 0.80-1.59; Pinteraction = 0.31 and 0.25, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding was significantly reduced in patients with or without an acute or recent myocardial infarction (HR: 0.65; 95% CI: 0.46-0.91 and HR: 0.71; 95% CI: 0.54-0.92; Pinteraction = 0.72) with abbreviated APT. CONCLUSIONS: A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).
1st Department of Cardiology University of Medical Sciences Poznan Poland
Brighton and Sussex University Hospitals NHS Trust Brighton United Kingdom
Cardiac Center King Fahad Armed Forces Hospital Jeddah Saudi Arabia
Cardiovascular Center OLV Hospital Aalst Belgium
Cardiovascular European Research Center Massy France
Clinical Trial Unit University of Bern Bern Switzerland
Department of Cardiology Angiology Intensive Care Medicine Saarland University Homburg Germany
Department of Cardiology Bern University Hospital Bern Switzerland
Department of Cardiology Catharina Hospital Eindhoven the Netherlands
Department of Cardiology Fujita Health University School of Medicine Toyoake Aichi Japan
Department of Cardiology Imelda Hospital Bonheiden Bonheiden Belgium
Department of Cardiology Maasstad Hospital Rotterdam the Netherlands
Department of Cardiology Zorgsaam Hospital Terneuzen the Netherlands
Division of Cardiology Geneva University Hospitals Geneva Switzerland
Faculty of Medicine and Life Sciences Hasselt University Hasselt Belgium
Hospital Alvaro Cunqueiro Vigo Spain
National University of Ireland Galway Ireland
Rabin Medical Center Sackler School of Medicine Tel Aviv University Tel Aviv Israel
Tan Tock Seng Hospital Singapore
University Clinic of Cardiology Ss Cyril and Methodius University Skopje Macedonia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024342
- 003
- CZ-PrNML
- 005
- 20221031100812.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jacc.2022.07.016 $2 doi
- 035 __
- $a (PubMed)36137672
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Smits, Pieter C $u Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands. Electronic address: SmitsP@maasstadziekenhuis.nl
- 245 10
- $a Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk / $c PC. Smits, E. Frigoli, P. Vranckx, Y. Ozaki, MC. Morice, B. Chevalier, Y. Onuma, S. Windecker, PAL. Tonino, M. Roffi, M. Lesiak, F. Mahfoud, J. Bartunek, D. Hildick-Smith, A. Colombo, G. Stankovic, A. Iñiguez, C. Schultz, R. Kornowski, PJL. Ong, M. Alasnag, AE. Rodriguez, V. Paradies, P. Kala, S. Kedev, A. Al Mafragi, W. Dewilde, D. Heg, M. Valgimigli, MASTER DAPT Investigators
- 520 9_
- $a BACKGROUND: The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. OBJECTIVES: The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction. METHODS: In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. RESULTS: NACE and MACCE did not differ with abbreviated vs nonabbreviated APT regimens in patients with an acute or recent myocardial infarction (n = 1,780; HR: 0.83; 95% CI: 0.61-1.12 and HR: 0.86; 95% CI: 0.62-1.19, respectively) or without an acute or recent myocardial infarction (n = 2,799; HR: 1.03; 95% CI: 0.77-1.38 and HR: 1.13; 95% CI: 0.80-1.59; Pinteraction = 0.31 and 0.25, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding was significantly reduced in patients with or without an acute or recent myocardial infarction (HR: 0.65; 95% CI: 0.46-0.91 and HR: 0.71; 95% CI: 0.54-0.92; Pinteraction = 0.72) with abbreviated APT. CONCLUSIONS: A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 _2
- $a dimaprit $x analogy a deriváty $7 D017259
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a krvácení $x chemicky indukované $x epidemiologie $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a infarkt myokardu $x farmakoterapie $7 D009203
- 650 12
- $a koronární angioplastika $x metody $7 D062645
- 650 _2
- $a inhibitory agregace trombocytů $x škodlivé účinky $7 D010975
- 650 _2
- $a polymery $7 D011108
- 650 _2
- $a stenty $7 D015607
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Frigoli, Enrico $u Clinical Trial Unit, University of Bern, Bern, Switzerland
- 700 1_
- $a Vranckx, Pascal $u Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
- 700 1_
- $a Ozaki, Yukio $u Department of Cardiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
- 700 1_
- $a Morice, Marie-Claude $u Cardiovascular European Research Center (CERC), Massy, France
- 700 1_
- $a Chevalier, Bernard $u Ramsay Générale de Santé, Interventional Cardiology Department, Institut Cardiovasculaire Paris Sud, Massy, France
- 700 1_
- $a Onuma, Yoshinobu $u National University of Ireland, Galway, Ireland
- 700 1_
- $a Windecker, Stephan $u Department of Cardiology, Bern University Hospital, Bern, Switzerland
- 700 1_
- $a Tonino, Pim A L $u Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands
- 700 1_
- $a Roffi, Marco $u Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland
- 700 1_
- $a Lesiak, Maciej $u 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Mahfoud, Felix $u Department of Cardiology, Angiology, Intensive Care Medicine, Saarland University, Homburg, Germany
- 700 1_
- $a Bartunek, Jozef $u Cardiovascular Center, OLV Hospital, Aalst, Belgium
- 700 1_
- $a Hildick-Smith, David $u Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom
- 700 1_
- $a Colombo, Antonio $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan and Humanitas Clinical and Research Center IRCCS, Rozzano-Milan, Italy
- 700 1_
- $a Stankovic, Goran $u Department of Cardiology, Clinical Center of Serbia, and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Iñiguez, Andrés $u Hospital Alvaro Cunqueiro, Vigo, Spain
- 700 1_
- $a Schultz, Carl $u Department of Cardiology, Royal Perth Hospital Campus, University of Western Australia, Perth, Western Australia, Australia
- 700 1_
- $a Kornowski, Ran $u Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Ong, Paul J L $u Tan Tock Seng Hospital, Singapore
- 700 1_
- $a Alasnag, Mirvat $u Cardiac Center, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
- 700 1_
- $a Rodriguez, Alfredo E $u Cardiac Unit Otamendi Hospital, Buenos Aires School of Medicine Cardiovascular Research Center (CECI), Buenos Aires, Argentina
- 700 1_
- $a Paradies, Valeria $u Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands
- 700 1_
- $a Kala, Petr $u University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Kedev, Sasko $u University Clinic of Cardiology, Ss Cyril and Methodius University, Skopje, Macedonia
- 700 1_
- $a Al Mafragi, Amar $u Department of Cardiology, Zorgsaam Hospital, Terneuzen, the Netherlands
- 700 1_
- $a Dewilde, Willem $u Department of Cardiology, Imelda Hospital Bonheiden, Bonheiden, Belgium
- 700 1_
- $a Heg, Dik $u Clinical Trial Unit, University of Bern, Bern, Switzerland
- 700 1_
- $a Valgimigli, Marco $u Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), CH-6900 Lugano, Switzerland
- 710 2_
- $a MASTER DAPT Investigators
- 773 0_
- $w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 80, č. 13 (2022), s. 1220-1237
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36137672 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100810 $b ABA008
- 999 __
- $a ok $b bmc $g 1854201 $s 1175632
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 80 $c 13 $d 1220-1237 $e 20220927 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
- LZP __
- $a Pubmed-20221017
